AMGN

Gilead Is a Hail Mary: 3 Better Stocks to Consider

After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead, which is down 25.2% (Note: our complete sector/industry performance rankings are available here). This article provides a review of why we believe owning Gilead is a high risk Hail Mary pass (i.e. Gilead’s growth prospects are not good), and we then review three stocks we consider more attractive.